Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delta-24-RGD in Recurrent Glioblastoma
NCT01582516Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- Jun 2010
- Primary completion
- Dec 2014
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of Ad5-D24RGD in glioblastoma (GBM), sponsored by Erasmus MC. Started Jun 2010; status: completed.
02
Drugs
Ad5-D24RGD
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01582516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01582516.